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Abstract
Capsaicin (CAP) is the chief active ingredient of natural chili peppers. It has culinary 
and medicinal benefits. CAP activates its receptor, transient receptor potential vanilloid 
subfamily 1 (TRPV1), which is expressed in the sensory and motor neurons, adipocytes, 
liver, vascular smooth muscle cells, neuromuscular junction, skeletal muscle, heart and 
brain. The specificity of CAP to activate TRPV1 is the fundamental mechanism for its 
medicinal benefits to treat pain, obesity, hypertension, and other diseases. Preclinical 
data from rodent model of high fat diet-induced obesity collectively suggest that CAP 
exerts its effects by activating TRPV1 signaling pathway, which stimulates thermogenic 
mechanisms in the white and brown adipose tissues to induce browning of white adipose 
tissues and brown adipose tissue thermogenesis. This leads to enhancement of metabolic 
activity and thermogenesis to counter obesity. Although CAP and its pungent and non-
pungent analogs are used in human clinical studies, their effects on satiety and energy 
expenditure have been the highlights of such studies. The precise mechanism of action of 
CAP has not been evaluated in humans. This article summarizes these data and suggests 
that long-term safety and tolerance studies are important for advancing CAP to treat 
human obesity.
Keywords: capsaicin, TRPV1, weight gain, obesity, adipose tissue, browning, brite, chili 
peppers, satiety, energy expenditure
1. Introduction
Capsaicin (CAP) is the most commonly occurring capsaicinoids in chili peppers. It is enriched 
in the pith and ribs of the pepper. The pungency and heat of CAP give a prominent place 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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as a chief spice ingredient in food industry. Chili peppers contain both pungent CAPoids 
and non-pungent capsinoids (Figure 1). CAP and dihydrocapsaicin belong to the group of 
pungent capsaicinoids, while non-pungent capsinoids like capsiate, dihydrocapsiate and 
nordihydrocapsiate have also been shown in preclinical studies to be beneficial against 
metabolic diseases. Chemically, CAP is known as 8-Methyl-N-vanillyl-trans-6-nonenamide. 
Biologically, CAP binds to and activates its receptor transient receptor potential vanilloid 
subfamily 1 (TRPV1) predominately expressed at the sensory nerve endings. Activation of 
TRPV1 by CAP is responsible for the intense heat and burning. CAP desensitizes TRPV1 and 
exerts its analgesic activity.
1.1. TRPV1: capsaicin receptor
TRPV1 is the first member of the vanilloid subfamily of the TRP superfamily of proteins. It is 
a non-selective cation channel protein discovered by Michael Caterina [1]. TRPV1 consists of 
six transmembrane domains, with intracellular N and C termini. The ion channel pore region 
is situated between the fifth and sixth transmembrane domains. Although CAP and resinif-
eratoxin are exogenous activators of TRPV1, it is endogenous activation is regulated by heat 
(~43°C), acidic pH (~5.5) and by inflammation mediators. Primarily, the expression of TRPV1 
is recognized in sensory neurons. Published literature suggests that TRPV1 is also expressed 
in various other tissues such as the neuromuscular junction [2–4], adipose tissue [5–7], liver [8, 
9], skeletal muscle [10, 11], vascular smooth muscle [12], etc. Also, published work suggests 
that TRPV1 in the brain. TRPV1 is involved in experimental model of temporal lobe epilepsy 
(TLE) [13]. Although TRPV1 expression has been reported in some brain areas [14], it is still 
Figure 1. Structure of capsinoids and capsaicinoids.
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Topical cream
0.01 or 0.025% for 6 weeks [15]
Psoriasis vulgaris Beneficial
Topical cream
0.075% for 8 weeks [16]
Painful diabetic neuropathy Beneficial
Topical cream
0.05% for several days [17]
Idiopathic trigeminal neuralgia Beneficial
Topical cream: 0.075% [18] or 0.025% for 2 months [19] Post mastectomy pain syndrome Beneficial
Topical cream
0.025% for 7 days [20]
Cluster headaches Beneficial
Topical cream
0.025% for 3 weeks [21]
Solar (brachioradial) pruritus Beneficial
Oral candy (taffy): 5–9 ppm [22] Oral mucositis pain Beneficial
Topical cream
0.075% for 4, 8 and 12 weeks [23]
Chronic distal painful polyneuropathy No beneficial 
effects




10 μM for 1 month (twice weekly) [25]
Severe bladder pain No Beneficial 
effects
Intranasal solution (0.1 mMol/L) every 2 or 3 days. 
Seven total treatments [26]




Topical cream: 0.075% for 8 weeks [27] or 0.025% for 
4 weeks [28]
Neuropathic pain Beneficial
Intravesical solution: 100 ml of 2 mM for 30 min. [29] Refractory detrusor hyperreflexia Beneficial
Topical: 0.025% for 4 weeks [30] Atypical odontalgia Beneficial
Topical cream: 5–10% [31] Refractory pain Beneficial
Topical cream: 0.075% for 4 weeks (four times a day) 
[32]




Intravesical solution (Pelargonic acid vanillamide): 
0.5 ml of 0.1 mmol/L solution per administration. Seven 
times in 14 days [33]
Perennial allergic rhinitis No beneficial 
effects
Topical cream
0.025% for 6 weeks [34]
Painful osteoarthritis Beneficial
Topical cream: 0.025–0.3% for 2 weeks to 4 months [35] Prurigo nodularis Beneficial
Oral red pepper powder
5 g/day for 5 weeks [36]
Functional dyspepsia Beneficial
Topical liniment
0.05% for 5 days (three times a day) [37]
Hemodialysis-related pruritus Beneficial
Topical ointment
0.006% for 4 weeks [38]
Intractable pruritus ani Beneficial
Oral capsaicin 0.25% [39] Burning mouth syndrome Beneficial
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Transdermal oleic capsaicin: containing patches 3 g per 
patch on 2 days with a 2-day interval between trials 
[40]
Stable coronary disease (to improve 
ischemic threshold)
Beneficial





UV induced immunosuppression Beneficial
Transdermal dermal patch: 640 μg/cm2, 8% w/w for 
60 min [43]
HIV-associated peripheral neuropathy Beneficial
Intraoperative wound instillation of ultra purified CAP 
instillation
1000 μg—single instillation [44]
Post herniotomy pain Beneficial
Topical ointment: 0.03% for 4 weeks (four times a day) 
[45]
Uremic pruritus Beneficial
CAP dermal patch: 8 or 0.04% for 30, 60 and 90 min 
[46]
Post herpetic neuralgia Beneficial
Topical capsaicin cream
0.05% for 3 weeks (thrice a day) [47]
Chronic soft tissue pain Beneficial
Topical civamide cream: 0.075% for 12 weeks (thrice a 
day) [48]
Osteoarthritis of the knee Beneficial
CAP hydrogel patch: 0.1% for 4 weeks (12 h a day) [49] Myofascial neck pain No beneficial 
effects
CAP cutaneous patch: 8% for 30 to 60 min [50] Peripheral neuropathic pain Beneficial




Topical CAPoid cream 0.01% nonivamide for 30 min a 
day for 21 days [52]
Chronic low back pain Beneficial
Oral capsules 0.4 mg per capsule (once daily for 
2 weeks followed by twice daily for 2 weeks) [53]
Chronic cough Beneficial
Oral Yanjiao 425 chili peppers containing 4 mg/g of 
CAP
1.25 g per day for 4 weeks [54]
Gestational diabetes mellitus Beneficial
Topical liposomal CAP
0.025% for two 6-week blocks with a gap of 2 weeks 
[55]
Post-herpetic neuralgia No beneficial effect
CAP cutaneous patch
8% for 60 min [56]
Lumbosacral pain Beneficial
CAP cutaneous patch
8% for 30 min [57, 58]
Neuropathy and painful diabetic 
peripheral neuropathy
Beneficial
Topical CAP gel: 0.01% or 0.025% for 14 days (thrice a 
day) [59]
Burning mouth syndrome Beneficial
Table 1. Capsaicin (type and dose) target disease effect.
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highly controversial. Nonetheless, the activation of TRPV1 and its ability to sense pain signal-
ing mechanism make it a valuable target for treating pain in humans.
Recent research has dramatically advanced TRPV1 as a target for treating various human 
diseases. Table 1 describes a list of preclinical and clinical studies for the beneficial effects of 
CAP against diseases.
Also, several preclinical and clinical studies have indicated that either capsiate alone or in 
combination with CAP is beneficial to counteract obesity and increase energy utilization 
[60–64]. However, the mechanisms behind such effect of CAP or capsiate still remain elusive.
2. Obesity and metabolic dysfunction
Obesity is a major health care issue in the world. About one third of the world’s population is 
either obese or overweight. When energy intake exceeds energy expenditure, the excess energy 
is stored as triglycerides in the white adipose tissues. This leads to increase in adiposity, which 
presents glucose intolerance, insulin resistance, dyslipidemia and metabolic dysfunctions. Thus, 
diet-induced obesity progressively leads to type 2 diabetes, hypertension, hypercholesterolemia, 
and cardiovascular diseases. Although diet restriction and exercise are good strategies to combat 
obesity, lack of consistent motivation to stick to healthy diet and regular exercise regimen leads 
to rebound weight gain when such interventions are stopped. Further, the pharmacotherapy for 
weight loss is associated with toxicities and side effects [65–68]. Bariatric surgeries are invasive 
procedures, not easily reversible but associated with high cost and potentials for adverse events.
2.1. CAP for obesity
There are overwhelming evidences for the effectiveness of CAP, its analogs and the whole 
chili pepper to ameliorate diet-induced obesity in rodents and humans [5, 69–72]. Majority 
of these research studies have been directed to analyze broader outcome in terms of increase 
in energy expenditure, metabolic activity or measurement of weight loss. Scientific research 
unambiguously supports the concept that activation of CAP receptor is important for the 
effect of CAP to counter diet-induce obesity [5–7, 73]. However, it still remains unclear 
whether TRPV1 expressed on adipose tissues or on the nerves that innervate the adipose 
tissues. Further, there is no direct evidence to either support or disregard the role of TRPV1 
expressed in central nervous system in this process. Although further research is warranted 
to clarify these mechanisms, published research works unambiguously support the benefits 
of CAP in abating obesity and metabolic syndrome in rodent models and humans. This article 
will discuss mechanisms emerging from studies focused on rodent models of obesity, which 
have translational value and help to interpret such mechanisms relevance to humans.
2.2. CAP and satiety
Since CAP is a pungent principle in chili peppers, its pungency has been regarded to satiety. 
Published work suggests that decreased appetite and increased energy expenditure were 
observed in humans who received red pepper in diet [74]. However, the ability of nonivamide, 
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a less pungent analog of CAP to reduce appetite [75] suggests that the pungency of CAP may 
not be directly related to the appetite regulation. Table 2 below summarizes the clinical data 
that on the appetite regulation of CAP in the form of chili pepper powder or analog.
One important point to remember is the form of CAP that is used for human studies that have 
yielded contradictory data on the effect of CAP on energy intake. The discrepancy in the qual-
ity and type of CAP and variability in the duration of exposure of CAP to participants make 
interpretation difficult. These studies also lack validations on the ability of the form or type 
of CAP to activate TRPV1. This must be addressed in future studies. Nonetheless, important 
questions regarding how CAP mediates satiety or enhances energy expenditure in humans 
still remain unclear. Research studies focusing the effect of CAP on animal models of obesity 
will be invaluable to analyze such mechanism(s).
2.3. Adipose depots, functions and TRPV1 expression
Obesity is characterized by increased adiposity. White adipose tissue (WAT) primarily performs 
the function of insulation and protection in the body, and is regarded as the store for fat as 
triglycerides. Brown adipose tissue (BAT) plays a critical role in expending energy as it burns 
the stored energy into heat by a process called thermogenesis. These adipocytes were classified 
based on their functions and they significantly differ in their mitochondrial content, expres-
sion of genes/proteins that regulate thermogenic mechanisms and their localization in the body. 
BAT represents a small portion depot located throughout the human body at numerous distinct 
places, especially within the chest (perivascular-around the aorta, common carotid artery, car-
diac veins and brachiocephalic artery), visceral cavity and subcutaneous region. BAT occurs 
along hollowed tissues (heart, trachea, lungs and esophagus), and in the visceral region, it is 
present around colon pancreas, kidneys, adrenal, liver and spleen [83–87]. Recently, a third type 
of adipose tissue called beige tissue or brite (brown in white) has been recognized, which are 
derived from WAT but express BAT specific thermogenic genes and proteins. In mammals, the 
beige-able adipose tissue locations haven identified as subcutaneous, inguinal and visceral [88] 
in rodents and supraclavicular [88], perirenal, visceral and subcutaneous depots [89] in humans.
Recent research has also characterized the expression of TRPV1 in these tissues. TRPV1 
expression has been shown on cultured adipocytes [90–92] and epididymal, subcutaneous 
and brown adipocytes [6, 7, 93]. The validation of expression of TRPV1 on adipose tissues 
suggests a plausible role of TRPV1 in the recruitment of BAT activity and thermogenesis and 
the induction of the molecular conversion of WAT to beige like cells.
2.4. CAP and browning of white adipose tissue
Beige adipose tissue is characterized by the enhanced expression of thermogenic genes and 
proteins that are not usually expressed at a higher level in WAT. They show enhanced expres-
sion of mitochondrial uncoupling protein-1 (UCP-1), bone morphogenetic protein 8b (BMP8b), 
and central metabolic sensor, sirtuin-1 (SIRT-1), peroxisome proliferator activated receptor 
gamma (PPARγ) and PR domain 16 containing protein (PRDM-16) and PPARγ coactivator 
1α (PGC-1α), which are recognized as factors regulating the beiging of WAT [94, 95]. Further, 
published literature suggests that Cd137 [96], Shox2 [97], Cited 1 [88], Tmem26 [96], Tbx1 [96, 
98], Bmp8b [99–101], ucp-1 [102, 103], SIRT-1-dependent mechanisms [6, 104], are considered 
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as markers for browning of WAT. Research work suggests that posttranslational modification, 
such as deacetylation, of PPARγ and PRDM-16 by SIRT-1 is involved in the beiging of WAT 
[6]. The deacetylation and stabilization of PPARγ and PRDM-16 by SiRT-1 been shown to 
induce browning of WAT in rodents [6, 7, 104]. CAP has been shown to induce browning of 
WAT in vitro [105] and in vivo [6] by activating SiRT-1 [6].
SiRT-1 plays a pivotal role in the regulation of cellular energy homeostasis. The phosphoryla-
tion and activation of SiRT-1 by cellular protein kinases like Ca2+/calmodulin-dependent protein 
kinase kinase β {CaMKKβ [106]}, CaMKIIα [6] and 5′-adenosine monophosphate-activated protein 
kinase {AMPK [6, 107–109]} has been shown to be important for the effect of CAP in browning of 
WAT. Preclinical data in mouse model of obesity suggests that feeding a high fat diet inhibits the 
expression and activity of TRPV1 in WAT and dietary CAP reversed it. CAP stimulates a robust 
Ca2+ influx via TRPV1, which stimulates CaMKII/AMPK-mediated SiRT-1 phosphorylation. 
This subsequently deacetylates PPARγ and PRDM-16 and promotes their stabilization. Figure 2 
describes SiRT-1-dependent mechanisms by which CAP enhances the deacetylation of PPARalha 
and PGC-1alpha to enhance fatty acid oxidation and mitochondrial biogenesis to promote the 
browning of WAT and counter obesity. However, such a mechanism has not been shown in 
humans and future studies are needed to address this.
2.5. CAP and BAT thermogenesis
Recognition of expression of TRPV1 in BAT poses important questions on the ability of CAP 
to enhance thermogenesis. Research approaches have aimed at activation of SiRT-1 [110–112], 
β3 adrenergic receptors [113–115], thyroid hormone, irisin [116, 117] and FGF21 [118] induc-
tion in BAT. Studies also suggest that secretory signaling mechanisms from muscle and liver, 
such as irisin and Fgf21 are also recognized humans [119]. In rodent model, TRPV1 activation 
protects against high fat diet-induced obesity by stimulating the expression of thermogenic 
genes and proteins in BAT [7, 105, 120–122]. Further, CAP enhances SiRT-1-depenent deacety-
lation and interaction of PPARγ and PRDM-16 in BAT [7].
The crosstalk between TRPV1 and beta-adrenergic action (possible mechanism illustrated in 
Figure 3) has been reported in the literature [123], which could influence an additive effect on 
the thermogenic mechanisms in BAT. Also, there are data suggesting that TRPV1 expressed 
on vagal afferents or intestinal mucosal afferents are important for the anti-obesity effect of 
CAP [124, 125]. Further studies are required to address these mechanisms.
Intraduodenal infusion of CAP 1.5 mg [76] Promoted satiety
Oral red chili peppers 1.03 g [77] Increase satiety
Oral red pepper 10 g [78, 79] Decreases appetite—Desire to consume fatty, salty, and sweet foods were 
decreased
Oral chili 30 g/day chili blend [80] No effect on energy intake
Oral CAP 135 mg/day [81] No effect on satiety and hunger
Oral CAP 1.03 mg [82] No effect on satiety
Table 2. CAP (type and dose) effect on appetite.
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Research studies are now beginning to address the physiological functions of TRPV1 in adi-
pose tissues. TRPV1 activation has been suggested to regulate adipogenesis and thermogenic 
pathways. It is also possible that along with the expression of TRPV1 on adipose tissue mem-
branes, the expression of TRPV1 on the nerves that innervate adipose tissues may contribute 
for the browning of WAT and BAT thermogenic mechanisms. This necessitates the develop-
ment of mouse strains that lack TRPV1 in specific tissues. Such a tool will be invaluable to 
delineate the precise role of TRPV1 signaling in metabolic tissues.
2.6. Safety and toxicological analyses of CAP
Studies have also addressed to evaluate the short-term and long-term effects of CAP in 
rodents and humans. In mice, oral administration of semisynthetic powdered CAP at a dose 
of 0.3125% caused benign tumors in cecum [126], Chili pepper extract-fed orally at a dose of 
800 mg/kg per day in male and 200 mg/kg/day in female showed no toxicity in mice [127]. 
Mice received CAP at a dose of 1.46 or 1.94 mg/kg by intraperitoneal injection showed increase 
in gastric cancer [128], while oral gavage of 2 and 10 mg/kg of CAP showed chemoprevention 
against tumorigenesis [129]. Studies have also demonstrated the oral LD50 of CAP for mouse 
and rat were 161.2 and 118.8 mg/kg, respectively, [130]. Studies in humans suggest that feed-
ing CAP in Women with gestational diabetes mellitus improved postprandial hyperglycemia, 
Figure 2. Mechanism by which CAP induces browning of WAT. CAP (CAP)-stimulated Ca2+ influx via TRPV1. Activates 
CaMKII/AMPK-dependent SiRT-1 activation. SiRT-1 deacetylates PPARalpha and PGC-1alpha. This increases fatty acid 
oxidation and mitochondrial biogenesis to promote browning of WAT, and counters diet-induced obesity.
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hyperinsulinemia, and fasting lipid disorders [54]. Also, CAP inhalation for cough challenge 
test had no single serious adverse event associated with CAP [131]. Further, a study in humans 
suggests that oral administration of 2.56 mg of CAP with every meal increased satiety and 
fullness and prevented over eating [77]. However, recent studies show that when along with 
a high fat diet CAP did not alter energy intake in mouse [6, 7]. However, there is still lack of 
clear evidence for the long-term effectiveness and safety of CAP in humans. Further studies 
are required to address this.
3. Conclusions and future perspectives
This article summarizes the preclinical and clinical data, which collectively suggest the anti-
obesity effect of CAP. However, the long-term efficacy and safety of TRPV1 agonist remain 
to be established. Although CAP is a natural product, its pungency is considered as a limita-
tion for oral use. Therefore, research should be geared to develop approaches to mask the 
pungency of CAP by coating it with polymers of agents, which decrease its burst release in 
the oral cavity and in the gastrointestinal tract. Since non-pungent analogs have been shown 
to be effective, efforts should be made to enhance their bioavailability and stability in the 
body. For example, capsiate, a non-pungent analog of CAP, is effective [62, 64, 132, 133] but 
issues exist on its stability [134], which requires attention. Recently, a site-specific delivery 
Figure 3. Model describing the neuronal effect of TRPV1. CAP (CAP) activates TRPV1 expressed in the innervating 
nerve of iWAT. This increases noradrenaline release, which activates β adrenergic receptors. The resultant Ca2+ influx 
enhances AMPK-dependent SiRT-1 activation. SiRT-1 deacetylates PPAR𝝲 and PRDM-16. This causes PPAR𝝲-PRDM-16 
interaction leading to BAT activation, which stimulates thermogenesis to ameliorate diet-induced obesity.
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system for CAP magnetic nanoparticles for obesity management has been reported [135, 136]. 
Such approaches should help in advancing the therapeutic efficacy of CAP. Further, efforts to 
deliver CAP at specific sites in the gastrointestinal tract through formulations such as enteric 
coated tablets and capsules will be beneficial to prevent its burst release in the stomach. Since 
human clinical study meta-analyses suggest that both CAPoids and capsinoids are beneficial 
in enhancing energy expenditure [64], dose products to combine them to counter obesity 
could be more effective.
Preclinical toxicological studies should be performed to demonstrate the safety and toler-
ance of CAP. These studies are important to clarify the perceptions that CAP could cause 
gastrointestinal disturbances and gastric ulcers [137–142]. However, such studies should use 
quality controlled pure CAP instead of chili pepper powder since the quality of CAP in those 
powders depends on the source of the peppers. Further, establishing the proof of concept for 
the anti-obesity effect of CAP using a proper dose and delivery system and validation of its 
bioavailability and pharmacokinetics are important for advancing its use in humans to treat 
obesity and associated metabolic complications.
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Abbreviations
CAP Capsaicin
TRP transient receptor potential
TRPV1 transient receptor potential vanilloid subfamily 1
SiRT-1 sirtuin-1
PPAR peroxisome proliferator activated receptor
PGC-1α PPARγ coactivator 1α
PRDM-16 PR domain 16 containing protein
BMP8b bone morphogenetic protein 8b
UCP-1 uncoupling protein 1
CaMKKβ Ca2+/calmodulin-dependent protein kinase kinase β
CaMKII Ca2+/calmodulin dependent protein kinase II
AMPK 5′-adenosine monophosphate activated kinase
WAT white adipose tissue
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BAT brown adipose tissue
LD50 lethal dose 50
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